Biotech | May 12, 2022
First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
An Integrated programme comprising GOQii device, Glucometer – Contour Plus+1 from Ascensia Diabetes Care India and personalised diabetes coaching
The demand for high-quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Toyobo will start looking at ways to use the knowhow from DMC’s sophisticated fermentation process technologies to enhance the efficiency of making its bioproducts
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
Dr. Muffazal Lakdawala performs the largest series of complete robotic gastric bypass surgery in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
